Sentences with phrase «developing small molecule therapies»
Novo Biosciences based of Bar Harbor, Maine is a regenerative medicine company developing small molecule therapies that reactivate and stimulate innate healing abilities in humans and animals.
https://mdibl.org/ Not exact matches
And Xenon, a Vancouver - based biotech, completed a US$ 31 - million private equity financing last April that will allow it to further develop its product pipeline, which consists of small - molecule therapies for select neurological, cardiovascular and metabolic diseases.
To investigate a possible new therapy to treat West Nile Virus disease, Kumar and her colleagues focused on a small «interfering» RNA molecule developed in her lab.
«We are also developing novel small molecules to selectively block the receptor for FnEDA as a potential anti-fibrotic therapy in humans.»
We are currently developing small molecule Nav1.1 activators that increase Nav1.1 currents and interneuron - dependent gamma oscillations in vitro and in vivo to develop novel therapies for conditions with impaired interneuron function, including AD and Dravet syndrome.
The cells generated in the Zeng lab may not only provide a potential unlimited source for cell replacement therapy for Parkinson's disease, but also offer an unprecedented opportunity to develop screening models for assessing small molecule drugs and to clarify the mechanisms of disease.
Yet one thing is clear: Major pharmaceutical manufacturers, originally skeptical about the prospects for large - molecule therapies, have long since joined the race to develop the treatments, acquiring, merging or partnering with small companies working on mAbs and other biologics.
Not a light read, this tome is bursting with information about monoclonal antibodies, from the history of how these therapies were first developed to new approaches such as conjugate therapy, which combines antibodies with small - molecule drugs.
Some research efforts are closer to clinical implementation, including developing improvements in clinical management of rare diseases and trials of small molecule therapies for inherited and mosaic genetic disorders.
This will fast - track new immune - modulating therapies for cancer patients by discovering and developing small molecule product candidates against immuno - oncology targets.
Specifically, the funding will enable Gladstone researchers to collaborate with Numerate, a South San Francisco - based chemoinformatics company, to develop small - molecule therapies that prevent the damaging effects of apoE4 on the brain.
To build upon the encouraging early discoveries, Helmsley renewed and expanded its Crohn's funding for the Institute in 2013 to begin new work with three major aims: 1) continue studies of individual genes to determine how genetic differences between Crohn's patients and healthy individuals contribute to the disease; 2) evaluate promising small molecules in disease - relevant studies and prioritize insights from genetics to help develop novel therapeutics; and 3) begin basic experimentation in animal models with Crohn's disease to provide the data necessary to begin testing new therapies in humans.
The company's lead candidate, GLN - 1001, is a first - in - class, orally available oncolytic small molecule, currently being developed as a potentially disease modifying therapy for glioblastoma by targeting specific vulnerabilities in tumor cells.
Given our extensive experiences in neuronal differentiation of hESCs [6], [7], [8] and the potential application of hESC - derived neurons in cell replacement therapies for neurodegenerative diseases, we designed a set of experiments aimed at developing a hESC - based automated assay for screening small molecules that have differential toxicity to hESC - derived NSCs and their differentiated neural progenies.